U.S. Ps Under the Paperwork Reduction Act of 1995, no persons are required to respond to a colle

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10505194	
	Filing Date		2004-08-19	
First Named Inventor Hidea		Hidea	iki Miura	
	Art Unit		2627	
	Examiner Name	Adam	i Giesy	
Attorney Docket Number		or	890050 497USPC	

				U.S.	PATENTS		Remove	
Examiner Initial*	Iner Cite   Patent Number   Nind   Issue Date   Name of Patentee or Applicant   Relev			Releva	es,Columns,Lines where evant Passages or Relevant res Appear			
	1	7167431	B2	2007-01-23	Miura et al.			
If you wisl	to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1	20020006579	A1	2002-01-17	Ichihara			
	2	20050083819	A1	2005-04-21	Kato et al.			
	3	20050088942	A1	2005-04-28	Miura et al.			
	4	20050089798	A1	2005-04-28	Miura et al.			
	5	20060269872	A1	2006-11-30	Miura			
If you wis	to ac	l dd additional U.S. Publis	hed Ap	plication citatio	n information please click the Ad-	d button	Add	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10505194	
iling Date		2004-08-19	
irst Named Inventor	Hideaki Miura		
rt Unit		2627	
xaminer Name	Adam	Giesy	
ttorney Docket Number		890050.497USPC	

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Тs	
	1	1300836	EP	A2	2003-04-09	Miyagawa et al.			
	2	2003054135	JP		2003-02-26	Mizushima et al.			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									

A

E

Examine Cite Include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), tilts of the item Initials\* No publisher, city and/or country where published.

1 Include name of the author (in CAPITAL LETTERS), tilts of the article (when appropriate) tilts of the item Initials\* No publisher, city and/or country where published.

If you wish to add additional non-patent literature document citation information please click the Add button Add

### EXAMINER SIGNATURE

Examiner Signature Date Considered Date Considered Date Considered Date Considered PEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include coor of this form with next communication to acciliant.

1 See Kind Codes of USPTO Patent Documents at yeary USPTO\_GOV or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Solitation 5.1.3. \*\*PG algorithms plant occurrents, he indicated of any pay of the legif of the Endpetior finals proceed in the Internet of the payment occurrent. "Med of document by the appropriate symbols as indicated on the document under WPO Stendard 51.1% if possible. \*Applicant is to place a check mark here if English language translation is attached.

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number			10505194	
	Filing Date		2004-08-19	
Art Unit		Hidea	iki Miura	
			2627	
		Adam	i Giesy	
Attorney Docket Number		or	890050 497USPC	

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

om of the signature.								
Signature	/Ronald Stern/	Date (YYYY-MM-DD)	2007-08-20					
Name/Print	Ronald Stem	Registration Number	59705					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

#### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.